Table 4.

Risk of mortality among propensity score-matched sample, colistin vs. new agents by AKI status

Final stepwise model—joint effect of AKI and treatment typea	OR estimate	Lower 95% CI	Upper 95% CI	p value
Ventilated at ANY point	15.87	5.69	44.23	< 0.0001
Age	1.03	1.01	1.06	0.0056
Rheumatologic disease	4.81	0.67	34.78	0.1196
Mild liver disease	3.01	1.08	8.44	0.0358
Malignancy	12.95	5.16	32.49	< 0.0001
New agent AKI vs. new agent no AKI	1.67	0.60	4.67	0.3312
Colistin no AKI vs. new agent no AKI	0.88	0.41	1.90	0.7415
Colistin AKI vs. new agent no AKI	5.37	2.31	12.49	< 0.0001
Colistin AKI vs. new agent AKIb	3.23	1.09	9.52	0.0347
Colistin AKI vs. colistin no AKIb	6.13	2.53	14.71	< 0.0001

AKI acute kidney injury

^aStepwise algorithm eliminating covariates with p value > 0.15 except for treatment and AKI

^bNot a model coefficient